| Heading: |
Pancreatic Enzyme Replacement Therapy: Shortages |
| Question ID: |
1758461 |
| UIN: |
26253 |
| House: |
Commons |
| Date tabled: |
2025-01-23 |
| Asking Member ID: |
5284 |
| Asking Member display name: |
David Chadwick
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
David Chadwick
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential economic impact of seeking unlicensed products as an alternative to Creon to mitigate ongoing pancreatic enzyme replacement therapy shortages on pharmac |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-01-30 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
There has been no assessment on the potential economic impact of seeking unlicensed products as an alternative to Creon.The Department is continuing to engage with suppliers of pancreatic enzyme replacement therapy (PERT) and special importers of unlicens... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |